PRM — Proteome Sciences Share Price
Last trade - 00:00- £8.56m
- £21.95m
- £4.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -48.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 4.75 | 5.13 | 7.78 | 5.03 | 4.89 | n/a | n/a | 0.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +100 | -76 | +1687.5 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.
Directors
- Christopher Pearce NEC (52)
- Mariola Sohngen CEO
- Stefan Fuhrmann FID
- Ian Pike CSO
- Richard Dennis EDR
- Martin Diggle NED
- Roger Mcdowell NID (66)
- Ursula Ney NID (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 10th, 1993
- Public Since
- October 3rd, 1995
- No. of Employees
- 35
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 295,182,056
- Address
- Coveham House, Downside Bridge Road, ADDLESTONE, KT11 3EP
- Web
- https://www.proteomics.com/
- Phone
- +44 2070432116
- Auditors
- Cooper Parry Group Limited
Latest News for PRM
Upcoming Events for PRM
Proteome Sciences PLC Annual Shareholders Meeting
Proteome Sciences PLC Annual Shareholders Meeting
Half Year 2025 Proteome Sciences PLC Earnings Release
Similar to PRM
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aoti
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 22:45 UTC, shares in Proteome Sciences are trading at 2.90p. This share price information is delayed by 15 minutes.
Shares in Proteome Sciences last closed at 2.90p and the price had moved by -7.64% over the past 365 days. In terms of relative price strength the Proteome Sciences share price has underperformed the FTSE All Share Index by -11.27% over the past year.
There is no consensus recommendation for this security.
Find out moreProteome Sciences does not currently pay a dividend.
Proteome Sciences does not currently pay a dividend.
Proteome Sciences does not currently pay a dividend.
To buy shares in Proteome Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 2.90p, shares in Proteome Sciences had a market capitalisation of £8.56m.
Here are the trading details for Proteome Sciences:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: PRM
Based on an overall assessment of its quality, value and momentum Proteome Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Proteome Sciences is 6.00p. That is 106.9% above the last closing price of 2.90p.
Analysts covering Proteome Sciences currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Proteome Sciences. Over the past six months, its share price has outperformed the FTSE All Share Index by +4.86%.
As of the last closing price of 2.90p, shares in Proteome Sciences were trading -15.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Proteome Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 2.90p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Proteome Sciences' management team is headed by:
- Christopher Pearce - NEC
- Mariola Sohngen - CEO
- Stefan Fuhrmann - FID
- Ian Pike - CSO
- Richard Dennis - EDR
- Martin Diggle - NED
- Roger Mcdowell - NID
- Ursula Ney - NID